10 results about "Ribociclib" patented technology

This invention provides a combination for use in treating cancers that express prostate-specific membrane antigen (PSMA). [Solution] A combination comprising a PD-1 inhibitor, a CTLA-4 inhibitor, and a radiolabeled compound of formula Ia for use in treating PSMA-expressing cancer in the subject. JPEG2026049728000042.jpg45132 The aforementioned combination comprises one or more further anticancer agents, wherein the further anticancer agents are selected from octreotide, lanreotide, vapreotide, pasireotide, satreotide, everolimus, temozolomide, telotristat, sunitinib, sulfatinib, ribociclib, entinostat, and pazopanib.

The invention provides a drug-drug salt of ribociclib (English name Ribociclib) and a non-steroidal anti-inflammatory drug containing a carboxylic acid group, a crystal of the drug-drug salt, a preparation method of the crystal, a pharmaceutical composition containing the crystal and application of the pharmaceutical composition. In the drug-drug salt, ribociclib is connected with a non-steroidal anti-inflammatory drug containing a carboxylic acid group through an intermolecular ionic bond. The drug-drug salt obtained by the invention can realize the synergistic interaction of ribociclib and a non-steroidal anti-inflammatory drug containing a carboxylic acid group, improves the anti-tumor activity of ribociclib, can improve the solubility of ribociclib, and improves the physical stability and bioavailability.

The invention belongs to the technical field of medicinal chemistry and nuclear medicine, and particularly relates to a PET probe based on radioactive metal labeling and a preparation method and application of the PET probe. Comprising a compound with a result shown in a formula (I). The radioactive probe disclosed by the invention has an obvious target to non-target ratio, can be used as a candidate probe for targeting CDK4 / 6, realizes precise positioning of tumors, and provides visual guidance for subsequent targeted therapy; due to the high specificity of the CDK4 / 6 gene, the CDK4 / 6 gene is expected to be developed into an accompanying diagnosis medicine, a clinical medication scheme is guided by quantitatively analyzing the CDK4 / 6 expression level in tumor tissue, and personalized treatment is achieved; and meanwhile, a new drug screening means and an analysis approach are provided for revealing the drug resistance mechanism of piperisib, ribociclib or abelsib and the like in breast cancer treatment.

This invention discloses a CDK4 / 6 inhibitor-loaded nanocarrier for targeting breast cancer, its preparation, and its application. Specifically, the nanoformulation of this invention contains: neutral phospholipids, anionic phospholipids, apolipoproteins and / or their mimic peptides, and a CDK4 / 6 inhibitor; wherein the CDK4 / 6 inhibitor is selected from the group consisting of abexicillin, ribociclib, palbociclib, dalcilib, or combinations thereof. The nanoparticles of this invention can efficiently kill breast cancer cells in vivo, inhibit breast cancer cell proliferation, and improve the prognosis of breast cancer.

This invention relates to the treatment of breast cancer in a subject, and the subject can be either a male or female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed selective estrogen receptor modulator (SERM) (tamoxifen, toremifene, raloxifene), gonadotropin-releasing hormone (GnRH) agonist (goserelin), aromatase inhibitor (AI) (letrozole, anastrozole, exemestane), cyclin-dependent kinase 4 / 6 (CDK 4 / 6) inhibitor (palbociclib (Ibrance), ribociclib (Kisqali), lerociclib, abemaciclib (Vorzenio), trilaciclib, lerociclib), mTOR inhibitor (everolimus), trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), alpelisib (Piqray) (an inhibitor of phosphatidylinositol-3-kinase subunit alpha (PI3Kα)), lapatinib, neratinib (Nerlynx), olaparib (Lynparza) (an inhibitor of the enzyme poly ADP ribose polymerase (PARP)), bevacizumab (Avastin), and / or fulvestrant treatments; metastasis in a subject suffering from breast cancer; HER2-positive; treating a subject suffering from ER mutant expressing breast cancer and / or treating breast cancer in a subject, by first determining the 18F-16β-fluoro-5α-dihydrotestosterone (18F-DHT) tumor uptake and identifying said subject as having AR-positive breast cancer based on 18F-DHT tumor uptake, comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound and a cyclin-dependent kinase 4 / 6 (CDK 4 / 6) inhibitor.

The utility model discloses preparation equipment for ribociclib tablets, which belongs to the technical field of tablet preparation and comprises a base, the upper surface of the base is fixedly connected with a plurality of support rods, the upper ends of the support rods are fixedly connected with a same storage tank, one side of the surface of the storage tank is fixedly connected with a processing component, and the processing component is fixedly connected with a plurality of blades. The upper end of the storage tank is fixedly connected with a tank cover, the lower surface of the tank cover is rotatably connected with a mixing assembly, the middle end of the upper surface of the base is fixedly connected with a transfer box, and the front surface of the transfer box is fixedly connected with a drying assembly. The ribociclib tablet crushing device is provided with the processing assembly, raw materials of ribociclib tablets are effectively and rapidly crushed, the uniformity of raw material particles is ensured, the mixing process of the raw materials, auxiliary materials and additives is accelerated by arranging the mixing assembly, the materials are prevented from being adhered to the inner wall of the tank body, excessive moisture in the materials is effectively removed by arranging the drying assembly, and the drying efficiency is improved. The hardness and the stability of the tablet are improved.

The present disclosure relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof. The present disclosure also relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof, (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof, and (3) a third agent which is an agent that regulates the PI3K / Akt / mTOR pathway or a pharmaceutically acceptable salt thereof.

This disclosure relates to adjuvant therapy for HR+ / HER2- stage II or III early breast cancer in adult patients. The method involves administering ribociclib (a CDK4 / 6 inhibitor) in combination with endocrine therapy.

The present disclosure relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof. The present disclosure also relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof, (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof, and (3) a third agent which is an agent that regulates the PI3K / Akt / mTOR pathway or a pharmaceutically acceptable salt thereof.